Baldi et al. (2003) [20]a
|
C, 9
PRT, 9 |
100 |
C, 50.1±3.9
PRT, 46.5±6.3 |
C, 36.4±9.3
PRT, 34.3±9.6 |
Biguanides, 11
Sulfonylureas, 7 |
Boudou et al. (2003) [21] |
C, 8
AEx, 8 |
100 |
C, 47.9±8.4
AEx, 42.9±5.2 |
C, 30.9±5.2
AEx, 28.3±3.9 |
C:
Metformin, 4
Metformin and gliclazide or glibenclamide, 1
AEx:
Metformin, 2
Metformin and gliclazide or glibenclamide, 4 |
Cuff et al. (2003) [19]a
|
C, 9
AEx, 9
AEx+PRT, 10 |
0 |
C, 60.0±8.7
AEx, 59.4±5.7
AEx+PRT, 63.4±7.0 |
C, 36.7±6.0
AEx, 32.5±4.2
AEx+PRT, 33.3±4.7 |
Oral hypoglycaemics |
Dunstan et al. (1997) [17] |
C, 12
AEx, 11
F, 12
AEx+F, 14 |
C, 75
AEx, 72.7
F, 83.3
AEx+F, 71.4 |
C, 53.0±7.0
AEx, 52.3±8.3
F, 54.1±8.2
AEx+F, 52.6±7.2 |
C, 29.7±4.3
AEx, 29.1±2.4
F, 29.8±4.4
AEx+F, 29.9±3.0 |
Antidiabetic and antihyperten- sive medication |
Dunstan et al. (1998) [22]a
|
C, 10
PRT, 11 |
C, 50
PRT, 72.7 |
C, 51.1±7.0
PRT, 50.3±6.6 |
C, 30.1±3.5
PRT, 28.3±2.7 |
Sulfonylureas, 4
Biguanides, 5
Sulfonylureas+biguanides, 10 |
Karstoft et al. (2013) [24]a
|
C, 8
AEx,
Continuous, 12
Intermittent, 12 |
C, 62.5
AEx,
Continuous, 66.7
Intermittent, 58.3 |
C, 57.1±8.5
AEx,
Continuous, 60.8±7.6
Intermittent, 57.5±8.3 |
C, 29.7±5.4
AEx,
Continuous, 29.9±5.5
Intermittent, 29.0±4.5 |
Antidiabetic and antihypertensive medication (abstained for 5 days prior to pre-/post-testing) |
Ligtenberg et al. (1997) [28] |
C, 28
AEx, 30 |
C, 35.7
AEx, 33.3 |
C, 61.0±5.0
AEx, 63.0±5.0 |
C, 31.2±3.3
AEx, 30.8±4.0 |
Oral hypoglycaemics and insulin |
Middlebrooke
et al. (2006) [29] |
C, 30
AEx, 22 |
At initial recruitment overall, 54.2 |
C, 64.6±6.8
AEx, 61.8±7.7 |
C, 29.9±5.4
AEx, 31.8±4.5 |
Oral hypoglycaemics |
Mourier et al. (1997) [30]a
|
C, 11
AEx, 10 |
At initial recruitment overall, 83.3 |
C, 46.0±10.0
AEx, 45.0±6.3 |
C, 30.1±5.3
AEx, 30.4±2.5 |
Metformin, 14;
Sulfonylurea, 3 |
Okada et al. (2010) [23] |
C, 17
AEx+PRT, 21 |
C, 64.7
AEx, 47.6 |
C, 64.5±5.9
AEx, 61.9±8.6 |
C, 24.5±2.9
AEx, 25.7±3.2 |
Study reported both groups received comparable medical intervention after registration for 3 months |
Ronnemaa et al. (1986) [31] |
C, 12
AEx, 13 |
At recruitment, 66.7 |
At recruitment overall, 52.5 (NR) |
NR |
Sulfonylureas, 18
Metformin+sulfonylureas, 10 |
Tamura et al. (2005) [18]a
|
D, 7
AEx+D, 7 |
D, 57.1
AEx+D, 42.8 |
D, 55.0±12.7
AEx+D, 46.3±7.4 |
D, 27.4±8.5
AEx+D, 27.1±7.7 |
D:
Sulfonylureas, 3
Metformin+sulfonylureas, 2
α-Glucosidase inhibitor, 2
D+AEx:
Sulfonylureas, 3
Metformin+sulfonylureas, 3
α-Glucosidase inhibitor, 1 |
Tan et al. (2012) [25] |
C, 10
AEx+PRT, 15 |
At recruitment:
C, 45.5
AEx+PRT, 44.4 |
C, 64.8±6.8
AEx+PRT, 65.9±4.2 |
C, 25.8±2.5
AEx+PRT, 25.2±2.5 |
Oral hypoglycaemics |
Tessier et al. (2000) [26] |
C, 20
AEx+PRT, 19 |
C, 55.0
AEx+PRT, 63.2 |
C, 69.5±5.1
AEx+PRT, 69.3±4.2 |
C, 29.4±3.7
AEx+PRT, 30.7±5.4 |
Glyburide:
C, 12
AEx+PRT, 10
Metformin:
C, 15
AEx, 14 |
Wing et al. (1988) [32] |
Include study 1:
P+D, 12
AEx+D, 10 |
At recruitment:
Study 1, 16.0 |
Study 1:
P+D, 52.5±8.9
AEx+D, 56.2±7.5 |
Study 1:
D+P, 37.2±1.8
AEx+D, 39.5±1.9 |
Study 1:
P+D, oral hypogylcaemics, 6
AEx+D, oral hypoglycaemics, 6 |
Winnick et al. (2008) [27] |
D, 9
AEx+D, 9 |
D, 33.3
AEx+D, 22.2 |
D, 50.9±3.2
AEx+D, 48.4±8.4 |
D, 32.0±5.3
AEx+D, 34.9±3.1 |
At the outset of the study, all participants discontinued diabetic related medication |